MOBILISE-D (820820)

  https://cordis.europa.eu/project/id/820820

  Horizon 2020 (2014-2020)

  Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

  Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice (IMI2-2017-13-07)

  drug discovery  ·  multiple sclerosis  ·  sensors  ·  health care services  ·  cardiology

  2019-04-01 Start Date (YY-MM-DD)

  2024-03-31 End Date (YY-MM-DD)

  € 49,911,564 Total Cost

  Description

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.

  Complicit Organisations

2 Israeli organisations participate in MOBILISE-D.